Study of Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline's (GSK)Respiratory Syncytial Virus (RSV)Maternal Unadjuvanted Vaccine in Healthy Pregnant Women (Aged 18 to 40 Years) and Their Infants
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
GlaxoSmithKline
Age
18–40
Sex
FEMALE
Healthy volunteers
Accepted
You may be eligible if
Maternal subjects
Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
Subjects who give written or witnessed/thumb printed informed consent after the study has been explained according to local regulatory requirements, and before any study specific procedures are performed. The informed consent given at screening should (consistent with local regulations / guidelines) either:
* include consent for both the maternal subject's participation and participation of the infant after the infant's birth, or
* include consent for the maternal subject's participation and expressed willingness to consider permitting the infant to take part after the infant's birth.
* Both mother and father should consent if local regulations/guidelines require it.
Age 18 to 40 years, inclusive, when informed consent is given.
Pre-pregnancy BMI 18.5 to 34.9, inclusive
Healthy as established by medical history and clinical examination before entering into the study.
At 28\^0/7 to 33\^6/7 weeks of gestation at the time of study vaccination (Visit 1), as established by last menstrual period (LMP) date corroborated by first or second trimester ultrasound examination (U/S).
\* If LMP and U/S do not correlate, default to U/S gestational age assessment. The level of diagnostic certainty of the gestational age should be established by using the Global Alignment of Immunisation safety Assessment in pregnancy gestation age assessment tool
Subject satisfying screening requirements
Singleton pregnancy
HIV negative, as assessed by local standard of care serologic tests conducted during the current pregnancy and before enrolment (Visit 1).
No fetal genetic abnormalities.
No significant congenital malformations, as assessed by level 2 ultrasound (also known as a fetal anomaly ultrasound scan or fetal morphology assessment) conducted after 18 weeks of gestation
Willing to provide cord blood
Willing to have the infant followed-up after delivery for a period of 12 months
Infant subjects
Live-born from the study pregnancy.
Re-signed (confirmed) written or witnessed/thumb printed informed consent for study participation of the infant obtained from the infant's mother and/or father and/or legally authorized representative, as applicable by local law, before performing any study specific procedure.
You may not be if
Maternal subjects
Medical conditions
History of allergic disease or reactions likely to be exacerbated by any component of the RSV vaccine
Hypersensitivity to latex
Significant complications in the current pregnancy such as:
* Gestational hypertension at ≥20 weeks of gestation in the absence of proteinuria in a woman with a previously normal blood pressure
* Gestational diabetes which is not controlled by diet and exercise
* Pre-eclampsia
* Eclampsia during current pregnancy
* Intrauterine growth restriction
* Placenta previa
* Placental abruption, placenta accreta/percreta/increta, chorioamnionitis or any abnormalities that in the opinion of Investigator can impair the maternal-fetal circulation
* Polyhydramnios
* Oligohydramnios
* Cervical suture in place
* Preterm labour or history of preterm labour in the current pregnancy
* Ongoing medical intervention to prevent preterm delivery or medical treatment for suspected preterm delivery
* Cholestasis
* Other pregnancy-related complications that in the Investigator's judgement would preclude participation of the subjects in an investigational vaccine trial or might pose risk to the subject due to participation in the study
Significant structural abnormalities of the uterus or cervix
History of prior stillbirth or neonatal death
History of preterm birth
History of ≥2 spontaneous abortions
Known or suspected HBV or HCV infection, based on medical history and clinical presentation
Known or suspected infection during the current pregnancy with Toxoplasma, Parvovirus B19, Syphilis, Zika, Rubella, Varicella, CMV or primary genital Herpes Simplex, based on medical history and clinical presentation
Active infection with tuberculosis, based on medical history and clinical presentation
Known or suspected impairment of the immune system or autoimmune disorder (based on medical history and physical examination; no laboratory testing required)
Lymphoproliferative disorder or malignancy within 5 years before vaccination (excluding effectively treated non-melanoma skin cancer)
Any clinically significant grade 1 hematological and/or biochemical laboratory abnormalities identified at screening, which are clinically significant for pregnant women in the second and third trimester
Grade ≥ 2 hematological and/or biochemical laboratory abnormalities identified at screening being clinically significant for pregnant women in the second and third trimester
Acute or chronic clinically significant conditions, that might pose additional risk to the subject due to participation in the study
Any conditions that, may interfere with subject's ability to comply with study procedures or receipt of prenatal care
Any condition which, would increase the risks of study participation to the unborn infant
Prior/Concomitant therapy
Prior receipt of a COVID-19 vaccine.
Prior receipt of an RSV vaccine
Use of any investigational or non-registered product other than the study vaccine(s)/product(s) during the period beginning 29 days before the dose of study vaccine/product or planned use during the study period
Planned administration/administration of any vaccine within 29 days before study vaccine administration and through Day 43 post-delivery, except seasonal influenza vaccines and dTpa/Tdap or tetanus, which may be administered according to standard of care ≥ 15 days before or after study vaccination
Administration of immunoglobulins, blood products or plasma derivatives within 3 months before study vaccination or planned administration through Visit 5
Administration of immune-modifying therapy within 6 months before the study vaccine/product dose, or planned administration through delivery. This includes but is not limited to:
* Prednisone, ≥ 5 mg/day or equivalent for ≥ 14 days. Topical, steroids are allowed. Inhaled steroids are allowed if ≤ 500µg/day of beclomethasone or fluticasone, or ≤ 800µg/day of budesonide.
Prior/Concomitant clinical study experience
Previous participation in a clinical trial of an RSV vaccine
Concurrently participating in another clinical study, in which the subject has been or will be exposed to an investigational or a non-investigational vaccine/product
Other exclusions
Alcoholism or substance use disorder within the past 24 months based on the presence of two or more abuse criteria
A local condition that precludes injection of the study drug or precludes assessment of local reactogenicity
Consanguinity of maternal subject and her partner (second degree cousins or closer)
Any study personnel or their immediate dependants, family, or household members
Infant subjects
Concurrently participating in another clinical study, in which the subject has been or will be exposed to an investigational or a non-investigational vaccine/product
Child in care
Clareo Health | Study of Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline's (GSK)Respiratory Syncytial Virus (RSV)Maternal Unadjuvanted Vaccine in Healthy Pregnant Women (Aged 18 to 40 Years) and Their Infants
